Tatva Chintan Pharma Chem Ltd
Tatva Chintan Pharma Chem Q3 FY26 earnings call: Revenue & Margins
Q3 FY26 earnings call: what management guided on revenue, margins and order book.
The short version
Existing Dahej plant revenue expected to reach INR 850-900 crores, covering PASC, SDA, electrolyte, and PTC products. Revenue growth of 20% to 30% year-on-year expected for FY '26 and similar growth anticipated for FY '27, bolstered by the commissioning of the new Jolva plant around Sep/Oct 2027 which will add new products and expand existing ones.
From Tatva Chintan Pharma Chem Ltd's Q3 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- Existing Dahej plant revenue expected to reach INR 850-900 crores, covering PASC, SDA, electrolyte, and PTC products.
- New Jolva plant targeting new agro products and expansion, contributing significantly from late 2027.
- Pharma & Agro new intermediates (3 each) expected to contribute INR 200-250 crores additional revenue in calendar year 2027, ramping up from current sales base.
- SDA segment projected to grow 25-30% in 2026 with capacity utilization around 55%, driven by Euro 7 norm demand surge starting 2027.
- Semiconductor chemicals expected to reach full commercialization around 2028 with very large volume potential.
2 more points management made on revenue & sales performance
Profitability & Margins
See what Tatva Chintan Pharma Chem Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- New plant at Jolva: Greenfield project with planned capex of INR 250-275 crores, expected execution within 18 months starting Q1 2026; aimed at commercializing new agro intermediate products and expanding existing ones.
- Dahej plant: Recent capex of ~INR 100 crores focused mostly on utilization expansion, optimization, and operational excellence rather than capacity increase.
- Jolva plant expected commissioning: Around September-October 2027, adding new products and revenue streams.
2 more points management made on capital expenditure plans
Top-ranked in Chemicals & Petrochemicals
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Tatva Chintan Pharma Chem Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- Tatva Chintan has onboarded two customers for the Structured Directing Agents (SDA) segment; one is in final contract signing and expected to start commercial supplies around August 2026.
- The second customer's negotiations are ongoing, with commercialization anticipated in the second half of the current calendar year.
- The Semiconductor Chemicals segment is in early stages; the company will execute its first plant trial order in the current quarter, with gradual full commercialization expected.
- The new Jolva plant, targeted for commissioning around September-October 2027, is expected to support new agro products and expanded existing product lines.
2 more points management made on order book & pipeline
Tatva Chintan Pharma Chem Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹134 Cr, net profit ₹10 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Tatva Chintan Pharma Chem Ltd's management said in earlier quarters
- Q1 FY27 earnings call analysis →
- Q2 FY26 earnings call analysis →
- Q1 FY26 earnings call analysis →
- Q3 FY25 earnings call analysis →
- Q4 FY25 earnings call →
- Q2 FY25 earnings call →
- Q1 FY25 earnings call →
- Q4 FY24 earnings call →
- Q3 FY24 earnings call →
- Q2 FY24 earnings call →
- Q1 FY24 earnings call →
- Q4 FY23 earnings call →
Others in Chemicals & Petrochemicals this season
- Balaji Amines Ltd (Q3 FY26)
Revenue from Operations for Q3FY26: ₹331.30 crore, compared to ₹320.59 crore in Q3FY25 (consolidated) and ₹304.68 crore in Q3FY25 (standalone). Key concall…
- Vidhi Specialty Food Ingredients Ltd (Q3 FY26)
94.5 Cr, down 4.1% YoY from Rs. Key concall takeaways from Vidhi Specialty Food Ingredients Ltd's Q3 FY26 earnings call — and how it ranks against sector peers.
- Bodal Chemicals Ltd (Q3 FY26)
5,046.6 Mn, up 13.3% YoY (Q3 FY25: Rs. Key concall takeaways from Bodal Chemicals Ltd's Q3 FY26 earnings call — and how it ranks against sector peers.
- Chemcon Speciality Chemicals Ltd (Q3 FY26)
Q3 FY26 Revenue from Operations:** ₹57.3 Cr (vs ₹54.4 Cr in Q3 FY25) — approx. Key concall takeaways from Chemcon Speciality Chemicals Ltd's Q3 FY26 earnings…
Frequently Asked Questions
What were Tatva Chintan Pharma Chem Ltd Q3 FY26 results?
Existing Dahej plant revenue expected to reach INR 850-900 crores, covering PASC, SDA, electrolyte, and PTC products. Revenue growth of 20% to 30% year-on-year expected for FY '26 and similar growth anticipated for FY '27, bolstered by the commissioning of the new Jolva plant around Sep/Oct 2027 which will add new products and expand existing ones.
What is Tatva Chintan Pharma Chem Ltd share price analysis?
Tatva Chintan Pharma Chem Ltd currently shows a neutral. The stock trades at a P/E of 76.8 with a market cap of ₹4,025 Cr. Investors should review the full earnings analysis for detailed insights.
Is Tatva Chintan Pharma Chem Ltd planning capital expenditure?
New plant at Jolva: Greenfield project with planned capex of INR 250-275 crores, expected execution within 18 months starting Q1 2026; aimed at commercializing new agro intermediate products and expanding existing ones.
Keep Tatva Chintan Pharma Chem Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.